Efficacy of Modified Treat-and-Extend Aflibercept Regimen for Macular Edema Due to Branch Retinal Vein Occlusion: 1-Year Prospective Study.
branch retinal vein occlusion
intravitreal aflibercept
modified treat-and-extend regimen
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
23 Jul 2020
23 Jul 2020
Historique:
received:
28
05
2020
revised:
21
06
2020
accepted:
21
07
2020
entrez:
29
7
2020
pubmed:
29
7
2020
medline:
29
7
2020
Statut:
epublish
Résumé
To assess the efficacy and safety of a modified treat-and-extend (mTAE) regimen of aflibercept for macular edema (ME) due to branch retinal vein occlusion (BRVO). This prospective multicentre intervention study evaluated 50 eyes of 50 patients enrolled from October 2016 to September 2017. The patients received intravitreal aflibercept (IVA) injections on an mTAE regimen for a total of 12 months. The main outcome measures were best-corrected visual acuity (BCVA) and central subfield thickness (CST) at 12 months. The baseline BCVA and CST were 0.33 (0.27) and 488 (171) µm (mean (standard deviation)), respectively. The BCVA and CST were significantly improved at month 12 (0.067 (0.19) LogMAR and 295 (110) µm; both The mTAE regimen of IVA injections for ME due to BRVO effectively improved BCVA and reduced CST, and thus might be an effective therapy to reduce the number of injections and visits.
Identifiants
pubmed: 32718095
pii: jcm9082360
doi: 10.3390/jcm9082360
pmc: PMC7464624
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Retina. 2013 Jul-Aug;33(7):1351-8
pubmed: 23538578
Ophthalmic Surg Lasers Imaging Retina. 2014 May-Jun;45(3):212-6
pubmed: 24716783
Acta Med Okayama. 2018 Feb;72(1):39-45
pubmed: 29463937
Expert Opin Drug Saf. 2014 Jun;13(6):785-802
pubmed: 24809388
Acta Ophthalmol. 2012 Mar;90(2):e98-e103
pubmed: 22066978
Retina. 2015 Aug;35(8):1489-506
pubmed: 26076215
N Engl J Med. 2010 Nov 25;363(22):2135-44
pubmed: 21105795
Ophthalmology. 2014 Jan;121(1):209-219
pubmed: 24112944
Retina. 2017 Apr;37(4):702-709
pubmed: 27471827
Ophthalmology. 2016 Jan;123(1):51-9
pubmed: 26477842
Ophthalmology. 2010 Jun;117(6):1102-1112.e1
pubmed: 20398941
Clin Ophthalmol. 2018 Aug 20;12:1487-1494
pubmed: 30154646
Arch Ophthalmol. 2008 Apr;126(4):513-8
pubmed: 18413521
Br J Ophthalmol. 2015 Feb;99(2):141-6
pubmed: 25271911
Ophthalmologica. 2016;235(4):203-7
pubmed: 27003517
PLoS One. 2017 Sep 12;12(9):e0184016
pubmed: 28898259
Int Ophthalmol. 2019 Jan;39(1):145-153
pubmed: 29274022
Trans Am Ophthalmol Soc. 2000;98:133-41; discussion 141-3
pubmed: 11190017
Am J Ophthalmol. 2007 Apr;143(4):679-80
pubmed: 17386275
Expert Opin Biol Ther. 2012 Oct;12(10):1299-313
pubmed: 22866908
Ophthalmic Res. 2018;60(1):29-37
pubmed: 29566387
Graefes Arch Clin Exp Ophthalmol. 2017 Apr;255(4):657-664
pubmed: 27743159
Dev Ophthalmol. 2010;47:111-135
pubmed: 20703046
Ophthalmology. 2016 Feb;123(2):330-336
pubmed: 26522708
Ophthalmology. 2016 Jun;123(6):1332-44
pubmed: 27039022
Ophthalmologica. 2011;225(3):150-4
pubmed: 21150231
Prog Retin Eye Res. 2014 Jul;41:1-25
pubmed: 24769221
Ophthalmology. 2015 Dec;122(12):2514-22
pubmed: 26391465
Br J Ophthalmol. 2014 Feb;98(2):195-9
pubmed: 24215032
Retina. 2015 May;35(5):1016-27
pubmed: 25574785
Retina. 2018 Jan;38(1):20-28
pubmed: 28145976